Last reviewed · How we verify
adjustment of immunosuppressant dosages
adjustment of immunosuppressant dosages is a Small molecule drug developed by CAMC Health System. It is currently FDA-approved.
At a glance
| Generic name | adjustment of immunosuppressant dosages |
|---|---|
| Sponsor | CAMC Health System |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient (PHASE4)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment (PHASE2)
- Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer (PHASE2)
- AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection (NA)
- A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia (PHASE3)
- Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia (PHASE2)
- Use of Tacrolimus and MTOR Inhibitors With Anticipatory Therapy vs. Tacrolimus and Mycophenolic Acid With Universal Prophylaxis in Renal Recipients at High Risk of Posttransplant Cytomegalovirus. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- adjustment of immunosuppressant dosages CI brief — competitive landscape report
- adjustment of immunosuppressant dosages updates RSS · CI watch RSS
- CAMC Health System portfolio CI
Frequently asked questions about adjustment of immunosuppressant dosages
What is adjustment of immunosuppressant dosages?
adjustment of immunosuppressant dosages is a Small molecule drug developed by CAMC Health System.
Who makes adjustment of immunosuppressant dosages?
adjustment of immunosuppressant dosages is developed and marketed by CAMC Health System (see full CAMC Health System pipeline at /company/camc-health-system).
What development phase is adjustment of immunosuppressant dosages in?
adjustment of immunosuppressant dosages is FDA-approved (marketed).